HT
Therapeutic Areas
Kotobuki Pharmaceutical Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Gilteritinib (XOSPATA®) | FLT3-mutated Relapsed/Refractory Acute Myeloid Leukemia | Approved |
| Tramadol HCl OD Tablets | Cancer & Chronic Pain | Approved |
| Zonisamide OD Tablets | Epilepsy | Approved |
| MARZULENE-S / AZULOXA | Gastritis & Peptic Ulcer | Approved |
| SUJANU® Combination Tablets | Type 2 Diabetes | Approved |
Leadership Team at Kotobuki Pharmaceutical
KS
Kazuhiro Satou
Director in charge of General Affairs
OY
Osami Yamaura
Director in charge of Sales
AN
Atsushi Noda
Director in charge of Manufacturing
TI
Tatsunori Iwai
Director in charge of Research Promotion
WU
Wataru Uchida, Ph.D.
Outside Director